{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:42Z","timestamp":1790383842376,"version":"4.1.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Serious bacterial infections such as bacteremia, endocarditis, osteomyelitis, and septic arthritis typically require prolonged intravenous antibiotics. Long-acting lipoglycopeptides (laLGPs), such as dalbavancin and oritavancin, offer extended treatment intervals for gram-positive infections that may benefit populations with barriers to traditional treatment, including persons who use drugs (PWUD individuals).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the effectiveness of laLGPs in managing serious bacterial infections in both PWUD and non-PWUD populations compared with standard-of-care (SOC) antibiotics.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This comparative effectiveness study using a target trial emulation framework included data extracted from the US Cerner Real World Data platform. Individuals hospitalized and discharged for serious bacterial infections between October 1, 2015, and October 1, 2022, were included in the analysis. Data were analyzed from July 7, 2023, to February 28, 2025.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Receipt of an laLGP (dalbavancin or oritavancin) vs SOC antibiotics.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome measure was a composite of readmission, emergency department visit, and inpatient death or discharge to hospice within 90 days post discharge from the index admission. Analyses were stratified by PWUD and non-PWUD status. Clone censor weighting was used to emulate a per-protocol analysis. Hazard ratios (HR) of time to the composite event and 95% CIs were calculated using bootstrapping.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 42\u202f067 included individuals, median age was 61 (IQR, 47-73) years, 24\u202f704 were male (58.7%), and 5047 (12.0%) were classified as PWUD. laLGPs were prescribed in 825 individuals (2.0%). There was no statistically significant difference in the composite outcome between the laLGP and SOC groups in both the PWUD (HR, 1.01; 95% CI, 0.88-1.13) and non-PWUD (HR, 0.93; 95% CI, 0.86-1.00) participants.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study of laLGPs vs SOC, findings suggested that laLGPs were effective as step-down treatment of serious gram-positive bacterial infections, offering comparable outcomes to those of SOC antibiotics in PWUD and non-PWUD individuals. Clinicians may consider laLGPs as alternative step-down options to SOC antibiotics for the treatment of serious gram-positive bacterial infections.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.11641","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:31:02Z","timestamp":1747827062000},"page":"e2511641","source":"Crossref","is-referenced-by-count":13,"title":["Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections"],"prefix":"10.1001","volume":"8","author":[{"given":"David","family":"Goodman-Meza","sequence":"first","affiliation":[{"name":"Kirby Institute, University of New South Wales Sydney, Sydney, Australia"},{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA (University of California, Los Angeles), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Weiss","sequence":"additional","affiliation":[{"name":"UCLA Center for HIV Identification, Prevention, and Treatment Services, Los Angeles"},{"name":"Department of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Poimboeuf","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA (University of California, Los Angeles), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Feng","sequence":"additional","affiliation":[{"name":"Medical Imaging Informatics Group, Department of Radiological Sciences, UCLA, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Vijayan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA (University of California, Los Angeles), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Martinello","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine at UCLA (University of California, Los Angeles), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"22","key":"zoi250396r1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.15585\/mmwr.mm6622a1","article-title":"Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence\u2014North Carolina, 2010-2015.","volume":"66","author":"Fleischauer","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"zoi250396r2","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1377\/hlthaff.2015.1424","article-title":"Hospitalizations related to opioid abuse\/dependence and associated serious infections increased sharply, 2002-12.","volume":"35","author":"Ronan","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"5","key":"zoi250396r3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ajem.2015.02.020","article-title":"Clinical profile of injection drug users presenting to the ED.","volume":"33","author":"Kievlan","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"12","key":"zoi250396r4","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"6","key":"zoi250396r5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamainternmed.2023.0923","article-title":"When oral therapy can replace intravenous antibiotics-changing practice as new data emerge.","volume":"183","author":"Heger","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi250396r6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ijantimicag.2015.07.001","article-title":"The history and evolution of outpatient parenteral antibiotic therapy (OPAT).","volume":"46","author":"Williams","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"zoi250396r7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx102","article-title":"Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users.","volume":"4","author":"Buehrle","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"zoi250396r8","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/jac\/dkq355","article-title":"Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service.","volume":"65","author":"Ho","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"zoi250396r9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx183","article-title":"Comparing injecting drug users with others receiving outpatient parenteral antibiotic therapy.","volume":"4","author":"Dobson","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"zoi250396r10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jhm.2582","article-title":"Perceptions and practices of physicians regarding outpatient parenteral antibiotic therapy in persons who inject drugs.","volume":"11","author":"Fanucchi","year":"2016","journal-title":"J Hosp Med"},{"issue":"12","key":"zoi250396r11","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2105\/AJPH.2015.302885","article-title":"Leaving the hospital against medical advice among people who use illicit drugs: a systematic review.","volume":"105","author":"Ti","year":"2015","journal-title":"Am J Public Health"},{"issue":"14","key":"zoi250396r12","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1503\/cmaj.130029","article-title":"Rates of readmission and death associated with leaving hospital against medical advice: a population-based study.","volume":"185","author":"Garland","year":"2013","journal-title":"CMAJ"},{"issue":"1","key":"zoi250396r13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"4","key":"zoi250396r14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: a long-half-life lipoglycopeptide.","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi250396r15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/526772","article-title":"Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.","volume":"46","author":"Billeter","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi250396r16","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"zoi250396r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106069","article-title":"Treatment of osteoarticular, cardiovascular, intravascular-catheter\u2013related and other complicated infections with dalbavancin and oritavancin: a systematic review.","volume":"56","author":"Thomas","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"zoi250396r18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/sur.2020.413","article-title":"Long-acting lipoglycopeptides for the treatment of bone and joint infections.","volume":"22","author":"Cooper","year":"2021","journal-title":"Surg Infect (Larchmt)"},{"issue":"8","key":"zoi250396r19","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"zoi250396r20","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab099","article-title":"Use of dalbavancin in infective endocarditis: a case series.","volume":"3","author":"Guleri","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"zoi250396r21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections.","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"1","key":"zoi250396r22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40360-020-00452-z","article-title":"Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs.","volume":"21","author":"Ahiskali","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"zoi250396r23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility.","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"zoi250396r24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae186","article-title":"Real-world dalbavancin use for serious gram-positive infections: comparing outcomes between people who use and do not use drugs.","volume":"11","author":"Zambrano","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"zoi250396r25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/QCO.0000000000000714","article-title":"Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.","volume":"34","author":"Bassetti","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"zoi250396r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2022.108120","article-title":"Cerner Real-World Data (CRWD)\u2014a de-identified multicenter electronic health records database.","volume":"42","author":"Ehwerhemuepha","year":"2022","journal-title":"Data Brief"},{"issue":"10","key":"zoi250396r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","article-title":"The Reporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) statement.","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"1","key":"zoi250396r28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy.","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"zoi250396r30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S2215-0366(18)30003-8","article-title":"The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.","volume":"5","author":"Larance","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"zoi250396r32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.12688\/wellcomeopenres.16431.2","article-title":"Healthcare use by people who use illicit opioids (HUPIO): development of a cohort based on electronic primary care records in England.","volume":"5","author":"Lewer","year":"2021","journal-title":"Wellcome Open Res"},{"issue":"9","key":"zoi250396r35","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac471","article-title":"Natural language processing and machine learning to identify people who inject drugs in electronic health records.","volume":"9","author":"Goodman-Meza","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zoi250396r36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40121-024-00933-2","article-title":"Dalbavancin sequential therapy for gram-positive bloodstream infection: a multicenter observational study.","volume":"13","author":"Rebold","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"1","key":"zoi250396r37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmacy10010001","article-title":"Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care.","volume":"10","author":"Antosz","year":"2021","journal-title":"Pharmacy (Basel)"},{"issue":"1","key":"zoi250396r38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12879-023-08725-8","article-title":"Oritavancin as sequential therapy for gram-positive bloodstream infections.","volume":"24","author":"Texidor","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"8","key":"zoi250396r39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"3","key":"zoi250396r40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40471-024-00346-2","article-title":"The clone-censor-weight method in pharmacoepidemiologic research: foundations and methodological implementation.","volume":"11","author":"Gaber","year":"2024","journal-title":"Curr Epidemiol Rep"},{"issue":"5","key":"zoi250396r41","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias: assessing the benefit of major surgery for elderly lung cancer patients using observational data.","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"6","key":"zoi250396r43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMc2114046","article-title":"Five-year outcomes of the Partial Oral Treatment of Endocarditis (POET) trial.","volume":"386","author":"Pries-Heje","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250396r44","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis.","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250396r45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection.","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250396r46","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac090","article-title":"Kimyrsa, an oritavancin-containing product: clinical study and review of properties.","volume":"9","author":"Hoover","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"zoi250396r47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"key":"zoi250396r29","unstructured":"AbbVie. Dalvance: coverage and reimbursement information. Published 2023. Accessed March 14, 2024. https:\/\/www.dalvance.com\/coding-and-reimbursement?cid=ppc_CVe5398a3d1a984efd92609d98f073db5f&&msclkid=034147d5193213a3b9d4202159104a65&utm_source=bing&utm_medium=cpc&utm_campaign=Dalvance_HCP_Branded_Max_Brand_US-DAV-230028&utm_term=reimbursement%20for%20dalvance%20claim&utm_content=Brand%20-%20Exact&gclid=034147d5193213a3b9d4202159104a65&gclsrc=3p.ds"},{"key":"zoi250396r31","unstructured":"Heslin? KCEA, Steiner? CA. Hospitalizations involving mental and substance use disorders among adults, 2012. Statistical Brief 191. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality; 2015. Accessed January 6, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310986\/table\/sb191.t4\/?"},{"key":"zoi250396r33","unstructured":"Fingar? KROP. Opioid-related and stimulant-related adult inpatient stays, 2012\u20132018. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality; 2021. Accessed January 6, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK568393\/table\/sb271.tab6\/"},{"key":"zoi250396r34","unstructured":"Centers for Diseases Control and Prevention. CDC All Drug Overdose (version 2). Accessed January 6, 2024. https:\/\/cdn.ymaws.com\/www.cste.org\/resource\/resmgr\/overdose_surveillance\/CDC_All_Drug_Definition_v2.pdf"},{"key":"zoi250396r42","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2023. Accessed February 28, 2025. https:\/\/www.R-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2834350\/goodmanmeza_2025_oi_250396_1747250356.46986.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:31:05Z","timestamp":1747827065000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2834350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.11641","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}